Simvastatin can also inhibit CRC liver metastasis by reducing cholesterol biosynthesis because hepatocyte growth factor (HGF) released from the liver induces SREBP2 and activates the c-Met/PI3K/AKT/mTOR axis in tumor cells to increase the cholesterol biosynthesis (121). Here, SREBF2 is linked to neoplasm.